125 related articles for article (PubMed ID: 34552051)
21. JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells
Zhang Z; Ye C; Liu J; Xu W; Wu C; Yu Q; Xu X; Zeng X; Jin H; Wu Y; Yan H
Cancer Biol Med; 2021 Sep; 19(5):651-68. PubMed ID: 34570444
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A; Morelli E; Samur MK; Botta C; Hideshima T; Bianchi G; Fulciniti M; Malvestiti S; Prabhala RH; Talluri S; Wen K; Tai YT; Richardson PG; Chauhan D; Sewastianik T; Carrasco RD; Munshi NC; Anderson KC
Blood Cancer Discov; 2021 Sep; 2(5):468-483. PubMed ID: 34568832
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
Desai SH; LaPlant B; Macon WR; King RL; Wang Y; Inwards DJ; Micallef I; Johnston PB; Porrata LF; Ansell SM; Habermann TM; Witzig TE; Nowakowski GS
Blood Cancer J; 2021 Sep; 11(9):160. PubMed ID: 34564694
[TBL] [Abstract][Full Text] [Related]
24. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility.
Gómez-Centurión I; Oarbeascoa G; García MC; López Fresneña MC; Martínez Carreño MJ; Escudero Vilaplana V; González-Haba E; Bailén R; Dorado N; Juárez LM; Rodríguez Macías G; Font López P; Encinas C; Bastos-Oreiro M; Anguita J; Sanjurjo M; Díez-Martin JL; Kwon M
Int J Hematol; 2022 Jan; 115(1):61-68. PubMed ID: 34553338
[TBL] [Abstract][Full Text] [Related]
25. The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond.
Strassl I; Schreder M; Steiner N; Rudzki J; Agis H; Künz T; Müser N; Willenbacher W; Petzer A; Neumeister P; Krauth MT
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572927
[TBL] [Abstract][Full Text] [Related]
26. Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
Wang CL; Wu VC; Tu HT; Huang YT; Chen SW; Chu PH; Wen MS; Huang HL; Chang SH
J Thromb Thrombolysis; 2022 Apr; 53(3):633-645. PubMed ID: 34557973
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
28. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.
Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD014739. PubMed ID: 34582035
[TBL] [Abstract][Full Text] [Related]
29. Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments.
Zhou J; Zhang M; Zhang Y; Shi X; Liu L; Yao R
Front Genet; 2021; 12():722132. PubMed ID: 34567073
[TBL] [Abstract][Full Text] [Related]
30. Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma.
Taenaka R; Takigawa K; Okamura K; Obara T; Nishimura N; Kohno K; Aoki K; Ogawa R
Transfus Apher Sci; 2021 Dec; 60(6):103279. PubMed ID: 34563457
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.
Benvenuto M; Ciuffa S; Focaccetti C; Sbardella D; Fazi S; Scimeca M; Tundo GR; Barillari G; Segni M; Bonanno E; Manzari V; Modesti A; Masuelli L; Coletta M; Bei R
Sci Rep; 2021 Sep; 11(1):19051. PubMed ID: 34561494
[TBL] [Abstract][Full Text] [Related]
32. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis.
Patel R; Ma J; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Daher M; Mehta R; Srour S; Weber DM; Thomas SK; Lee HC; Patel KK; Orlowski RZ; Shpall ES; Champlin RE; Saini N; Qazilbash MH
Am J Hematol; 2021 Dec; 96(12):E455-E457. PubMed ID: 34559916
[No Abstract] [Full Text] [Related]
33. A 3D-Bioprinted Multiple Myeloma Model.
Wu D; Wang Z; Li J; Song Y; Perez MEM; Wang Z; Cao X; Cao C; Maharjan S; Anderson KC; Chauhan D; Zhang YS
Adv Healthc Mater; 2022 Apr; 11(7):e2100884. PubMed ID: 34558232
[TBL] [Abstract][Full Text] [Related]
34. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [
Ghai A; Fettig N; Fontana F; DiPersio J; Rettig M; Neal JO; Achilefu S; Shoghi KI; Shokeen M
EJNMMI Res; 2021 Sep; 11(1):97. PubMed ID: 34586539
[TBL] [Abstract][Full Text] [Related]
35. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
36. Benefit with daratumumab maintenance.
Romero D
Nat Rev Clin Oncol; 2021 Nov; 18(11):676. PubMed ID: 34580476
[No Abstract] [Full Text] [Related]
37. High-output heart failure associated with primary plasma cell leukaemia due to arteriovenous shunting: a case report.
Sudo Y; Inagaki H
Eur Heart J Case Rep; 2021 Sep; 5(9):ytab353. PubMed ID: 34557641
[TBL] [Abstract][Full Text] [Related]
38. Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.
Ramos TL; García-Guerrero E; Caballero-Velázquez T; Rodríguez-Gil A; Caracuel-García R; Nufer M; Robles-Frías MJ; Barbado MV; Pérez-Simón JA
Bone Marrow Transplant; 2021 Dec; 56(12):3049-3058. PubMed ID: 34556806
[TBL] [Abstract][Full Text] [Related]
39. Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells.
Kobari L; Auclair M; Piau O; Ferrand N; Zaoui M; Delhommeau F; Fève B; Sabbah M; Garderet L
Leukemia; 2022 Feb; 36(2):540-548. PubMed ID: 34556797
[TBL] [Abstract][Full Text] [Related]
40. Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.
Ravi G; Gonsalves WI
Cancer Treat Res Commun; 2021; 29():100444. PubMed ID: 34555665
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
